Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy
Authors:
Open Access
- 1 December 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (49) , e13372
Abstract
Intrahepatic cholangiocarcinoma (ICC) originates from the secondary branch of the bile duct and the intrahepatic bile duct epithelial cells, and is a rare pathological type of primary liver cancer. Recently, apatinib has been successfully used for a variety of malignancies. A 23-year-old female was noted with intermittent right upper abdominal distension, abdominal pain, and vomiting after eating for more than 1 month. The enhanced CT scan revealed multiple intrahepatic lesions, portal vein and right branch tumor emboli were present. Combined with the patient's medical history and pathology and immunohistochemistry, the diagnosis was confirmed as locally advanced unresectable ICC (cT4N1M1, Stage IVB). The disease progressed after six cycles of gemcitabine plus capecitabine chemotherapy. She received oral apatinib treatment since September 30, 2017. Due to related adverse reactions, the patient could not tolerate the treatment, and the subsequent reduction therapy was given. On April 11, 2018, the review of CT evaluation suggested that the disease was progressed. Hence, in this patient, apatinib as second-line treatment for advanced ICC showed a progression-free survival with 6 months. Apatinib as second-line treatment for advanced ICC is effective, and the adverse effects are tolerable. However, the efficacy and safety of apatinib in the treatment of ICC need to be further confirmed by large sample of prospective randomized controlled trials.Keywords
This publication has 30 references indexed in Scilit:
- A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancerCancer Chemotherapy and Pharmacology, 2013
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivoCancer Science, 2011
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium StudyJournal of Clinical Oncology, 2010
- Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancerInvestigational New Drugs, 2010
- Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractorinessInvestigational New Drugs, 2010
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver MetastasesJAMA, 2009
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trialBritish Journal of Cancer, 2009
- Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the LiteratureThe Oncologist, 2007
- Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and HypertensionAmerican Journal of Kidney Diseases, 2007
- Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001British Journal of Cancer, 2006